在炎症性肠病中准 pyroptosis:一种潜在有效的治疗方法
Wei-Wei Dong1,2,3, Tao Liu1,2,3, Li-Xia He4
1The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730030, Gansu Province, China.
World journal of gastroenterology
|December 8, 2025
概括
热,一个被编程的细胞死亡,驱动着炎症性肠病 (IBD) 的进展. 抑制 pyroptosis 为IBD提供了一个有前途的治疗策略,针对NLRP3,caspases和GSDMD等关键炎症组分.
科学领域:
- 胃肠道学和免疫学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎和克罗恩病,以慢性肠道炎症为特征.
- 热,一种由Gasdermin D (GSDMD) 裂变介导的亲炎性编程细胞死亡途径,通过NLRP3/caspase-1和caspase-4/5/11炎症酶激活显著促进IBD病变.
研究的目的:
- 系统地审查用于IBD的热致死抑制剂的机制和治疗潜力.
- 探索在IBD管理中针对热致死治疗的挑战和未来方向.
主要方法:
- 对 pyroptosis 抑制剂的临床前和临床证据的文献综述.
- 分析小分子化合物,生物制剂和重用药物,以向热灭途径.
- 评估克服挑战的策略,如药物特异性,输送和安全.
主要成果:
- 针对NLRP3,caspases或GSDMD的 Pyroptosis抑制剂在抑制炎症酶激活和减轻炎症方面表现有前途.
- 目前正在研究各种治疗方式,包括小分子和生物制剂.
- 结合治疗与现有的IBD治疗可能会提高临床疗效.
结论:
- 向热死是一种有前途的治疗途径,用于IBD的精确管理.
- 在临床翻译中,应对特异性,交付和安全性方面的挑战至关重要.
- 对组合疗法的进一步研究是有必要的,以优化IBD治疗结果.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
01:21Inflammatory Bowel Disease V: Surgical Management
428
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
428
01:29Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431